SCHEMBL3279260

SCHEMBL3279260

CC(=O)CC(=O)OC(C)Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.50
GAA P10253 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
TSHR P16473 3/20 0.35
ALDH1A1 P00352 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
FAAH O00519 4/20 0.33
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM1 P11229 1/20 0.31
TBXA2R P21731 1/20 0.31
HTT P42858 1/20 0.31
GALR3 O60755 1/20 0.30
MAPT P10636 1/20 0.30
BLM P54132 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
CNR1 P21554 1/20 0.30
CNR2 P34972 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11278832 1.00 MGAM (0.50) MGAMGAASIMGAM2TSHR
SCHEMBL9065292 0.87 MGAM (0.38) MGAMGAASIMGAM2TSHR
SCHEMBL28119418 0.85 MGAM (0.55) MGAMGAASIMGAM2TSHR
SCHEMBL9065300 0.81 LDHA (0.36) TSHRALDH1A1TDP1FAAHMAPT
SCHEMBL6837511 0.80 MGAM (0.55) MGAMGAASIMGAM2TSHR
SCHEMBL29438274 0.80 MGAM (0.55) MGAMGAASIMGAM2TSHR
SCHEMBL182320 0.80 MGAM (0.55) MGAMGAASIMGAM2TSHR
SCHEMBL8751786 0.80 MGAM (0.55) MGAMGAASIMGAM2TSHR
SCHEMBL27761012 0.79 MGAM (0.48) MGAMGAASIMGAM2TDP1
SCHEMBL20481946 0.78 MGAM (0.52) MGAMGAASIMGAM2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4408827-A1 A NEW INTERMEDIATE FOR PREPARATION OF OXAZOLE COMPOUNDS DSM IP Assets B.V. (NL) 2024-08-07 EP disclosed
EP-4408828-A1 A PROCESS FOR PREPARATION OF OXAZOLE COMPOUNDS DSM IP Assets B.V. (NL) 2024-08-07 EP disclosed
CN-117209418-A Preparation and purification method of high-purity nicardipine hydrochloride 华仁医学研究(安徽)有限公司 2023-12-12 CN disclosed
EP-4192820-A1 A PROCESS FOR PREPARATION OF OXAZOLE COMPOUNDS DSM IP Assets B.V. (NL) 2023-06-14 EP disclosed
WO-2023052104-A1 A PROCESS FOR PREPARATION OF OXAZOLE COMPOUNDS DSM IP ASSETS B.V. (NL) 2023-04-06 WO disclosed
WO-2023052103-A1 A NEW INTERMEDIATE FOR PREPARATION OF OXAZOLE COMPOUNDS DSM IP ASSETS B.V. (NL) 2023-04-06 WO disclosed
WO-2022053318-A1 A PROCESS FOR PRODUCING OXAZOLE COMPOUNDS DSM IP ASSETS B.V. (NL) 2022-03-17 WO disclosed
WO-2022028941-A1 A PROCESS FOR PREPARATION OF OXAZOLE COMPOUNDS DSM IP ASSETS B.V. (NL) 2022-02-10 WO disclosed
CN-107879935-A Method for synthesizing vinyl carboxylate 王建华 2018-04-06 CN disclosed
CN-106456609-A Substituted indazole compounds as irak4 inhibitors 奥瑞基尼探索技术有限公司 2017-02-22 CN disclosed
US-7696210-B2 Gonadotropin releasing hormone receptor antagonists WYETH (US) 2010-04-13 US disclosed
EP-1758895-A1 GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS Wyeth a Corporation of the State of Delaware (US) 2007-03-07 EP disclosed
CN-1874989-A Process for preparing -or (R) -4-halo-3-hydroxybutyric acid esters LONZA AG (CH) 2006-12-06 CN disclosed
US-20060019965-A1 Gonadotropin releasing hormone receptor antagonists WYETH (US) 2006-01-26 US disclosed
WO-2006009734-A1 GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS WYETH (US) 2006-01-26 WO disclosed
CN-1578660-A Lactam-containing compounds and derivatives thereof as factor xa inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-02-09 CN disclosed
EP-0216542-B1 DIHYDROPYRIDINE DERIVATIVES THE GREEN CROSS CORPORATION (JP) 1991-12-11 EP disclosed
US-4849429-A CARDIOVASCULAR, HYPOTENSIVE, ENZYME INHIBITOR THE GREEN CROSS CORPORATION (JP) 1989-07-18 US disclosed
EP-0063747-B1 2-SUBSTITUTED OR UNSUBSTITUTED AMINOCARBONYLOXYALKYL-1,4-DIHYDROPYRIDINES BANYU PHARMACEUTICAL CO., LTD. (JP) 1987-12-09 EP disclosed
EP-0216542-A1 Dihydropyridine derivatives THE GREEN CROSS CORPORATION (JP) 1987-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019965-A1 Gonadotropin releasing hormone receptor antagonists GNRHR, GHRHR, LHCGR MGAM 2872/4885GAA 1721/4885SI 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.